Scientists at Saint Louis University have made two key discoveries that could lead to the first-ever human testing of a drug to target the adenovirus, which causes a number of severe upper-respiratory infections and is one of many viruses that causes the common cold.
There are currently no drugs approved specifically to treat adenovirus infections in large part because there has been no animal model in which to test drug candidates, a key prerequisite before testing in humans.
SLU researchers and their collaborators, however, have made two breakthrough findings: an animal model suitable for adenovirus testing – in this case using Syrian hamsters – and a drug that successfully attacks the adenovirus in those animals. The drug, hexadecyloxypropyl-cidofovir or CMX001, is currently under development by Chimerix, Inc. as a biodefense agent to meet the threat of smallpox or monkeypox viruses and as an antiviral agent in transplant patients.
The SLU research is published the week of May 19 in an early online edition of the Proceedings of the National Academy of Sciences.
“This is exciting news and a major step forward in finding a drug to treat adenovirus infections in humans,” said William Wold, Ph.D., professor and chair of the department of molecular microbiology and immunology at the Saint Louis University School of Medicine and the study’s lead author.
One of the key obstacles to finding an animal model for adenovirus testing involves the fact that the virus is generally species-specific; meaning the human version of the virus doesn’t replicate well in animals commonly used in laboratory research.
The SLU researchers, however, found that the adenovirus replicates in Syrian hamsters (also called golden hamsters) with suppressed immune systems in much the same manner as it replicates in humans whose immune systems are weakened – making Syrian hamsters ideal for animal model testing.
“We are pleased to see that CMX001, a drug candidate showing broad antiviral activity that is being developed under a federal grant for smallpox, also has potential benefit against adenovirus,” said George R. Painter, Ph.D., president and CEO of Chimerix.
Said Samuel Stanley Jr., director of the Midwest Regional Center of Excellence for Biodefense and Emerging Infectious Diseases Research (MRCE): “It is exciting to see work funded by the National Institute of Allergy and Infectious Diseases’ MRCE program lead to potential new therapies for this important virus.”
There are 52 known serotypes, or strains, of adenovirus in humans. They generally cause acute upper respiratory infections including colds, tonsillitis and ear infections, but they can also cause conjunctivitis, gastroenteritis and bladder infections.
Most people are able to recover from an adenovirus infection, but in some young children and people with weakened immune systems, adenovirus infections can turn virulent and even deadly. Adenovirus can also cause disease and even death in organ transplant recipients. Severe adenovirus outbreaks have occurred among groups of military recruits likely due to crowded living conditions.
CMX001 is an oral pro-drug, or derivative, of cidofovir, a drug developed by Gilead Sciences, Inc. to treat a type of retinitis in AIDS patients. Chimerix licensed from Gilead the rights to develop CMX001.
Cidofovir has long been a possible candidate to treat a number of virus infections, including the herpes virus, poxvirus and adenovirus infections in humans. The drug, however, is quite toxic to the liver and kidneys and is not available in oral form, which limits widespread use.
Using the new animal model, the SLU researchers found that CMX001 provided protection from the adenovirus when it was administered prophylactically (before infection with the virus) or therapeutically (after infection). The scientists found that the drug worked by greatly reducing the ability of the virus to replicate in key organs, mostly notably the liver.
The SLU team also found that CMX001 was much less toxic and far more powerful than cidofovir. In addition, scientists discovered, two weeks after infection with the virus CMX001 had reduced the viral load in the liver and blood to undetectable levels.
First time-lapse footage of cell activity during limb regeneration
25.10.2016 | eLife
Phenotype at the push of a button
25.10.2016 | Institut für Pflanzenbiochemie
Ultrafast lasers have introduced new possibilities in engraving ultrafine structures, and scientists are now also investigating how to use them to etch microstructures into thin glass. There are possible applications in analytics (lab on a chip) and especially in electronics and the consumer sector, where great interest has been shown.
This new method was born of a surprising phenomenon: irradiating glass in a particular way with an ultrafast laser has the effect of making the glass up to a...
Terahertz excitation of selected crystal vibrations leads to an effective magnetic field that drives coherent spin motion
Controlling functional properties by light is one of the grand goals in modern condensed matter physics and materials science. A new study now demonstrates how...
Researchers from the Institute for Quantum Computing (IQC) at the University of Waterloo led the development of a new extensible wiring technique capable of controlling superconducting quantum bits, representing a significant step towards to the realization of a scalable quantum computer.
"The quantum socket is a wiring method that uses three-dimensional wires based on spring-loaded pins to address individual qubits," said Jeremy Béjanin, a PhD...
In a paper in Scientific Reports, a research team at Worcester Polytechnic Institute describes a novel light-activated phenomenon that could become the basis for applications as diverse as microscopic robotic grippers and more efficient solar cells.
A research team at Worcester Polytechnic Institute (WPI) has developed a revolutionary, light-activated semiconductor nanocomposite material that can be used...
By forcefully embedding two silicon atoms in a diamond matrix, Sandia researchers have demonstrated for the first time on a single chip all the components needed to create a quantum bridge to link quantum computers together.
"People have already built small quantum computers," says Sandia researcher Ryan Camacho. "Maybe the first useful one won't be a single giant quantum computer...
14.10.2016 | Event News
14.10.2016 | Event News
12.10.2016 | Event News
25.10.2016 | Earth Sciences
25.10.2016 | Power and Electrical Engineering
25.10.2016 | Process Engineering